key: cord-0888570-pig8856f
authors: Gaziano, L.; Giambartolomei, C.; Pereira, A. C.; Gaulton, A.; Posner, D. C.; Swanson, S. A.; Ho, Y. L.; Iyengar, S. K.; Kosik, N. M.; Vujkovic, M.; Gagnon, D. R.; Bento, A. P.; Beltrao, P.; Barrio Hernandez, I.; Ronnblom, L.; Hagberg, N.; Lundtoft, C.; Langenberg, C.; Pietzner, M.; Valentine, D.; Allara, E.; Surendran, P.; Burgess, S.; Zhao, J. H.; Peters, J. E.; Prins, B. P.; Danesh, J.; Devineni, P.; Shi, Y.; Lynch, K. E.; DuVall, S. L.; Garcon, H.; Thomann, L.; Zhou, J. J.; Gorman, B. R.; Huffman, J. E.; O'Donnell, C. J.; Tsao, P. S.; Beckham, J. C.; Pyarajan, S.; Muralidhar, S.; Huang, G.
title: Actionable druggable genome-wide Mendelian randomization identifies repurposingopportunities for COVID-19
date: 2020-11-23
journal: nan
DOI: 10.1101/2020.11.19.20234120
sha: 88078b2528b38b171f8c992f5e95aee684f9eb4b
doc_id: 888570
cord_uid: pig8856f

Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization (MR) analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2: P=1.6x10^-6, IFNAR2: P=9.8x10^-11, and IL-10RB: P=1.9x10^-14) using cis-eQTL genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared eQTL signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.

genome 96 97 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint 4 Abstract 98 Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint INTRODUCTION 113 COVID-19 has caused a global pandemic resulting in excess mortality, stress on healthcare 114 systems and economic hardship. Even if an efficacious vaccine against SARS-CoV-2 virus 115 emerges in 2021, it could take several years to achieve herd immunity. Hence, there is a need to 116 rapidly identify drugs that can minimize the burden of COVID-19. Although large randomized 117 trials have begun to successfully identity drugs that can be repurposed to address COVID-19, 1,2 118 most drugs evaluated so far have failed to show efficacy and have been largely confined to 119 hospitalized or critically-ill patients. Therefore, it is pressing to identify additional drugs that can 120 be repurposed for early management in COVID-19. Genetic variants acting in "cis" on druggable protein levels or gene expression that encode 134 druggable proteins can provide powerful tools for informing therapeutic targeting, as they mimic 135 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint the on-target (beneficial or harmful) effects observed by pharmacological modification. 7 Such 136 Mendelian randomization (MR) analyses have been used to suggest repurposing opportunities 137 for licensed drugs. 8, 9 MR analysis that focuses on actionable druggable genes, defined as genes 138 that encode the protein targets of drugs that are licensed or in the clinical phase of drug 139 development, could therefore serve as a fast and robust strategy to identify drug-repurposing 140 opportunities to prevent the complications and mortality due to COVID-19. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint 7

Overall analysis plan 152 Figure 1 describes the overall scheme of the analyses. First, we identified all proteins that are 153 therapeutic targets of approved or clinical-stage drugs. Next, we selected conditionally-154 independent genetic variants that act locally on plasma levels of these proteins or tissue-specific 155 gene expression that encode these proteins. We proposed that these variants were instrumental 156 variables and conduct two-sample MR analyses 12 using a trans-ancestry meta-analysis of 7 CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Interferon alpha receptor 2 (IFNAR2) and interleukin 10 receptor beta (IL-10RB) both act as Although rs2834167 was associated with IL10RB expression in 18 tissues, it was not associated 241 with IFNAR2 expression in any tissue (Supplementary Table 8 ). The A allele at rs2834167, 242 which is associated with lower IL10RB gene expression but higher plasma IL-10RB, was 243 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. Table 9 ). This mimics agonistic effects of IFNAR2 through recombinant type-I IFNs, which are 262 known to have an anti-angiogenic effect, at least in part through reduced VEGF/VEGFR2 263 signaling 20,21 , and decrease tryptase levels in a phase-2 trial using recombinant type-I IFN in 264 patients with mastocytosis 22 , a condition that causes proliferation of mast cells. rs13050728 was 265 not associated at P<4×10 -5 (our Bonferroni corrected P value) with any phenotype beyond 266 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint plasma VEGFR2 and TPSG1 and gene expression of IFNAR2 and IL10RB (Supplementary   267   Table 9 ), indicating that this variant is unlikely to exhibit widespread horizontal pleiotropy. 268 Also, the chances of substantial bias due to MR violations is low 23 since the variant is not 269 strongly associated with other risk factors that could alter the likelihood of SARS-CoV-2 testing 270 or hospitalization of COVID-19 patients. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint 13 pQTLs for ACE2 291 Stepwise conditional analysis for plasma ACE2 measured by Olink revealed one pQTL, 292 rs5935998 (P=1.4×10 -21 ), which is in high LD with a previously reported cis-pQTL 293 (rs12558179) for ACE2 (r 2 =0.89 in 1000G EUR) 24 , and a secondary suggestive signal hospitalization. There were no other reported phenome-wide scan results at P <4×10 -5 for 312 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; 14 rs4830976, which is at least in part due to the lack of reported X-chromosome results from a 313 large proportion of GWAS. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint

To identify drug-repurposing opportunities to inform trials against COVID-19, we conducted a 325 large-scale MR analysis of protein and gene expression data. We first updated the "actionable" 326 genome to an enlarged set of 1,263 human proteins and provided evidence for 700 of these as 327 targets for drugs with some potential relevance to COVID-19. By testing more than a thousand 328 of these using several of the largest currently available human genetic datasets, we provide 329 evidence for drug targets of type-I IFNs (IFNAR2) and ACE2 modulators (ACE2) as priority 330 candidates for evaluation in randomized trials of early management in COVID-19.

Our finding that ACE2 may play an important role in COVID-19 is unsurprising given its well-333 known relevance to SARS-CoV-2. Since ACE2 acts as the primary receptor for SARS-CoV-2, 334 increased expression of ACE2 has been hypothesized to lead to increased susceptibility to Our study has several strengths. We provide an updated catalog of all actionable protein targets 411 and drugs that are amenable to causal inference investigation through human genetics. By 412 combining several of the most comprehensive datasets currently available and linking genetic 413 variation with gene expression, plasma protein levels and COVID-19, we were able to robustly 414 evaluate over one thousand actionable drug targets. We took multiple steps to minimize potential 415 biases and confounding that could invalidate our actionable druggable-genome-wide MR 416 analysis, such as using colocalization methods to minimize the chances of false positive results 417 due to confounding by LD. We were careful to reduce the impact of horizontal pleiotropy by 418 restricting our proposed instruments to variants acting in cis and performing phenome-wide scan 419 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint to ensure they were only associated with gene expression of the tested gene or downstream 420 phenotypes (vertical pleiotropy), but unmeasured sources can remain.

Our analysis also has limitations. Though we make use of instrumental variants from multiple 423 data sources, none cover the entire actionable druggable genome, were ancestry-specific or were 424 derived from COVID-19 patients. However, we managed to recover credible biological targets 494 We proposed pQTL instruments from two sources of publicly available data that reported 535 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint KQg/view) Results for each ancestry-stratum were meta-analyzed along with the HGI (summary 536 statistics already meta-analyzed from contributing studies) for COVID hospitalization using 537 METAL software 56 with inverse-variance weighting and fixed effects. 558 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint Identifying pQTLs using Olink assay 560 We performed stepwise conditional analysis to identify cis-pQTL proposed instruments for 561 proteins that passed our significance and colocalization thresholds and were one of 354 unique were genotyped using the UK Biobank Affymetrix Axiom array, followed by phasing using 566 SHAPEIT3 and imputation on the Sanger Imputation Server using a 1000 Genomes Phase 3-567 UK10K imputation panel. Alleles were tested against Olink proteins using SNPTEST v2.5.2 and 568 adjusted for age, sex, plate, time from blood draw to processing, season and the first 5 principal 569 components. Conditional analysis was performed by adjusting for peak variants until no 570 association fell below 5×10 -6 . 571 572 Phenome-wide scan 573 We conducted a phenome-wide scan for variants with the following goals. First, we want to 574 evaluate that our proposed instruments could reproduce the known phenotype associations (e.g. 575 disease, biomarkers) ascribed to the drug that are due to on-target effects. Secondly, we want to 576 identify if our proposed instruments are associated with comorbidities associated with greater 577 likelihood of SARS-CoV-2 testing or predictors of hospitalization in COVID-19 patients, as this 578 could potentially highlight the presence of certain biases. 23 Also, for genes that were the target of 579 licensed drugs, we checked whether the disease indication was also a risk factor for COVID-19 580 outcomes, as this might introduce a bias analogous to confounding by indication in MR.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors declare no competing interests.

Acknowledgements 619 We are grateful to the Host Genetic Initiative for making their data publicly available (full 620 acknowledgements can be found here: https://www.covid19hg.org/acknowledgements/). This is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint Connecting lines represent significant Hi-C interactions. C, Set of rsIDs used as proposed 663 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary 689 Report

Remdesivir for the Treatment of Covid-19 -Final Report

The support of human genetic evidence for approved drug 693 indications

Improving the odds of drug development success through human 695 genomics: modelling study

and protection against coronary heart disease

From Natural Resistance to a New Anti-HIV Strategy. Viruses

The druggable genome and support for target identification and 702 validation in drug development

The interleukin-6 receptor as a target for prevention of coronary 704 heart disease: a mendelian randomisation analysis

Effect of a single dose of the interleukin-6 receptor antagonist 706 tocilizumab on inflammation and troponin T release in patients with non-ST-elevation 707 myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host 710 genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Million Veteran Program: A mega-biobank to study genetic 713 influences on health and disease

Commentary: how to report instrumental variable 715 analyses (suggestions welcome)

Understanding the Assumptions Underlying Instrumental 717

Variable Analyses: a Brief Review of Falsification Strategies and Related Tools

The Genotype-Tissue Expression (GTEx) project

Genomic atlas of the human plasma proteome

Genetic architecture of host proteins interacting with SARS-CoV-2. 723 bioRxiv

Interferons at age 50: past, current and future impact on biomedicine

Co-regulatory networks of human serum proteins link genetics to 727 disease

PhenoScanner: a database of human genotype-phenotype associations

Endothelial cell functions impaired by interferon in vitro: Insights into the 733 molecular mechanism of thrombotic microangiopathy associated with interferon therapy

Treatment of adult systemic mastocytosis with interferon-alpha: 736 results of a multicentre phase II trial on 20 patients

Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials

Genetic Associations With Plasma Angiotensin Converting Enzyme 2 742 Concentration: Potential Relevance to COVID-19 Risk

Eliciting priors and relaxing the single causal variant assumption in 745 colocalisation analyses

A potential therapeutic role for angiotensin-converting enzyme 2 in 747 human pulmonary arterial hypertension

Lessons from SARS: control of 749 acute lung failure by the SARS receptor ACE2

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 751 virus-induced acute lung injury

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues 753 Using Clinical-Grade Soluble Human ACE2

Human recombinant soluble ACE2 in severe COVID-19

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for 757

Patients With COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development 759 of COVID-19

Comparative Replication and Immune Activation Profiles of SARS-CoV-2 761 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the 762 Pathogenesis of COVID-19

Impaired type I interferon activity and inflammatory responses in 764 severe COVID-19 patients

Auto-antibodies against type I IFNs in patients with life-threatening 766 COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening 768 COVID-19

Presence of Genetic Variants Among Young Men With Severe 770 COVID-19

SARS-CoV-2 is sensitive to type I interferon pretreatment

Antiviral activities of 774 type I interferons to SARS-CoV-2 infection

Critical Role of Type III Interferon in Controlling SARS-CoV-2

Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-778

Coronavirus 2 In Vitro When Administered After Virus Infection

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-781 19 medical countermeasures. bioRxiv

Triple combination of interferon beta-1b, lopinavir-ritonavir, and 783 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, 784 randomised, phase 2 trial

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY 786 trial results. medRxiv

NIAID Stops COVID-19 Trial Enrollment Over Adverse Events

Evidence for Gastrointestinal Infection of SARS-CoV-2

Histopathology and ultrastructural findings of fatal COVID-19 791 infections in Washington State: a case series

Neurologic Manifestations of Hospitalized Patients With Coronavirus 793 Disease

Multiorgan and Renal Tropism of SARS-CoV-2

Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv

ChEMBL: towards direct deposition of bioassay data

Matrix eQTL: ultra fast eQTL analysis via large matrix operations

Nucleic Acid Ligands With Protein-like Side Chains: Modified 803

Aptamers and Their Use as Diagnostic and Therapeutic Agents

Aptamer-based multiplexed proteomic technology for biomarker 806 discovery

A Natural Language Processing System for National

Surveillance in the US Department of Veterans Affairs

METAL: fast and efficient meta-analysis of 810 genomewide association scans

A Bayesian framework for multiple trait colocalization from

Infection in Human Intestinal Epithelial Cells. Cell Rep 32, 107863 (2020).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.19.20234120 doi: medRxiv preprint